X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2670) 2670
Publication (356) 356
Book Review (84) 84
Newsletter (23) 23
Book Chapter (6) 6
Newspaper Article (6) 6
Conference Proceeding (2) 2
Magazine Article (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bortezomib (2331) 2331
humans (2001) 2001
index medicus (1875) 1875
multiple myeloma (1641) 1641
hematology (1353) 1353
oncology (1287) 1287
multiple myeloma - drug therapy (1228) 1228
male (990) 990
female (974) 974
aged (934) 934
middle aged (922) 922
dexamethasone (827) 827
antineoplastic combined chemotherapy protocols - therapeutic use (766) 766
treatment outcome (671) 671
lenalidomide (665) 665
stem-cell transplantation (665) 665
thalidomide (642) 642
adult (612) 612
therapy (563) 563
antineoplastic agents - therapeutic use (492) 492
care and treatment (490) 490
chemotherapy (474) 474
survival (462) 462
boronic acids - administration & dosage (460) 460
pyrazines - administration & dosage (458) 458
cancer (452) 452
thalidomide - analogs & derivatives (452) 452
dexamethasone - administration & dosage (439) 439
transplantation (397) 397
boronic acids - therapeutic use (391) 391
multiple myeloma - mortality (390) 390
multiple myeloma - pathology (390) 390
aged, 80 and over (388) 388
multiple myeloma - therapy (386) 386
pyrazines - therapeutic use (386) 386
thalidomide - administration & dosage (385) 385
antineoplastic combined chemotherapy protocols - adverse effects (320) 320
drug therapy (320) 320
prognosis (309) 309
stem cells (299) 299
medicine & public health (296) 296
thalidomide - therapeutic use (289) 289
recurrence (288) 288
melphalan (284) 284
lenalidomide plus dexamethasone (281) 281
disease-free survival (279) 279
combination (274) 274
research (270) 270
trial (267) 267
analysis (257) 257
plus dexamethasone (254) 254
stem cell transplantation (249) 249
proteasome inhibitors (244) 244
retrospective studies (238) 238
patients (236) 236
boronic acids - adverse effects (233) 233
pyrazines - adverse effects (232) 232
transplantation, autologous (232) 232
hematology, oncology and palliative medicine (227) 227
multiple myeloma - diagnosis (227) 227
multiple-myeloma (227) 227
myeloma (218) 218
prednisone (216) 216
survival analysis (213) 213
clinical trials (212) 212
antineoplastic agents - adverse effects (204) 204
cyclophosphamide (203) 203
dosage and administration (200) 200
carfilzomib (198) 198
pharmacology & pharmacy (193) 193
elderly-patients (192) 192
animals (186) 186
multiple myeloma - genetics (186) 186
apoptosis (185) 185
antineoplastic combined chemotherapy protocols - administration & dosage (184) 184
combination therapy (183) 183
article (180) 180
antineoplastic agents - administration & dosage (178) 178
patient outcomes (178) 178
dexamethasone - therapeutic use (175) 175
health aspects (175) 175
bortezomib - administration & dosage (171) 171
medical research (169) 169
peripheral neuropathy (167) 167
survival rate (167) 167
thalidomide - adverse effects (167) 167
diagnosis (166) 166
remission induction (163) 163
open-label (162) 162
hematopoietic stem cell transplantation (161) 161
risk factors (161) 161
hemic and lymphatic diseases (157) 157
antineoplastic agents - pharmacology (155) 155
multiple myeloma - complications (152) 152
relapse (151) 151
follow-up studies (149) 149
clinical trials as topic (147) 147
neoplasm staging (146) 146
proteasome inhibitor bortezomib (146) 146
drug administration schedule (145) 145
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2643) 2643
French (17) 17
German (16) 16
Chinese (11) 11
Japanese (7) 7
Spanish (4) 4
Polish (2) 2
Russian (2) 2
Czech (1) 1
Korean (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 11/2007, Volume 357, Issue 21, pp. 2133 - 2142
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9758, pp. 2075 - 2085
Journal Article
Blood, ISSN 0006-4971, 11/2011, Volume 118, Issue 22, pp. 5752 - 5758
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2010, Volume 28, Issue 30, pp. 4621 - 4629
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2010, Volume 28, Issue 30, pp. 4630 - 4634
Journal Article
Journal Article
Journal Article
Leukemia, ISSN 0887-6924, 11/2009, Volume 23, Issue 11, pp. 2147 - 2152
We present a pooled update of two large, multicenter MM-009 and MM-010 placebo-controlled randomized phase III trials that included 704 patients and assessed... 
dexamethasone | multiple myeloma | PREDNISONE | THERAPY | ONCOLOGY | lenalidomide | BORTEZOMIB | HEMATOLOGY | myelosuppression | MELPHALAN | Clinical trials | Dosage and administration | Dexamethasone | Management | Drug therapy | Multiple myeloma
Journal Article
by Liu, BJ and Wang, Y and Bai, M and Wang, D and Zhao, J and Zhang, M and Sun, SR
CLINICAL THERAPEUTICS, ISSN 0149-2918, 06/2019, Volume 41, Issue 6, pp. 1186 - 1198
Purpose: At present, a diverse array of treatment regimens are available for systemic amyloid light chain (AL) amyloidosis. Both cyclophosphamide + thalidomide... 
SURVIVAL | DIAGNOSIS | ORAL MELPHALAN | amyloidosis | immunoglobulin light chain | melphalan | PRIMARY SYSTEMIC AMYLOIDOSIS | BORTEZOMIB | STAGING SYSTEM | thalidomide | cyclophosphamide | PHARMACOLOGY & PHARMACY | HIGH-DOSE MELPHALAN | OUTCOMES | AL AMYLOIDOSIS | CARDIAC BIOMARKERS
Journal Article
Journal Article
Journal Article